MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Cholinergic deficits in Parkinson Disease

    R. Miller, D. Dhavale, J. O’Shea, E. Franklin, N. Cairns, R. Perrin, M. Campbell, J. Perlmutter, P. Kotzbauer (St. Louis, USA)

    Objective: To determine whether loss of cholinergic projections to cortical and limbic regions contributes to the development of dementia in Parkinson’s disease (PD). Background: PD…
  • 2023 International Congress

    The examination of the relationship between limited thoracic mobility and shoulder joint function in individuals with extrapyramidal syndrome

    C. Bouzineki, A. Christakou, S. Kanellopoulou, X. Arabatzi, V. Sakellari (Athens, Greece)

    Objective: To explore the effect of limited thoracic mobility on shoulder joint functionality in extrapyramidal patients over 60 years of age. Background: The extrapyramidal motor…
  • 2023 International Congress

    Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for patients with Parkinson’s disease and motor fluctuations: Results from the Phase 3 randomized, active-controlled BouNDless study

    O. Rascol, A. Albanese, A. Ellenbogen, J. Ferreira, N. Giladi, T. Gurevich, S. Hassin-Baer, J. Hernandez-Vara, S. Isaacson, K. Kieburtz, P. Lewitt, L. Lopez-Manzanares, CW. Olanow, R. Pahwa, W. Poewe, H. Sarva, F. Stocchi, T. Yardeni, L. Adar, L. Salin, N. Lopes, N. Sasson, R. Case, A. Espay (Toulouse, France)

    Objective: Determine the efficacy, safety, and tolerability of ND0612 versus oral immediate-release levodopa/carbidopa (IR-LD/CD) in people with Parkinson’s disease (PwP) experiencing motor fluctuations. Background: ND0612…
  • 2023 International Congress

    Classification and genotype-phenotype relationships of GBA1 variants and Parkinson’s disease: MDSGene Systematic Review

    T. Usnich, M. Rossi, S. Schaake, N. Schell, J. Böhm, N. Steffen, C. Krüger, R. Alcalay, K. Lohmann, C. Klein (Lübeck, Germany)

    Objective: To provide a comprehensive and systematic literature review of variants in the glucocerebrosidase 1 gene (GBA1) linked to Parkinson’s disease (PD). Background: Approximately 10% of patients with PD…
  • 2023 International Congress

    Post encephalitic dystonia-ataxia syndrome

    A. Elavarasi, F. Mustafa, A. Garg, M. Tripathi, D. Vibha, R. Singh, B. Mishra (New Delhi, India)

    Objective: To describe a young man with post encephalitc dystonia-ataxia with transient worsening following a febrile episode Background: We had a 19 year old young…
  • 2023 International Congress

    Eye tracking paradigm to identify disease-specific behavioral biomarkers in neurodegeneration

    M. Habibi, B. Coe, D. Brien, H. Riek, A. Janzen, W. Oertel, D. Munoz (Marburg, Germany)

    Objective: Rapid-eye movement (REM) sleep behavior disorder (RBD) has been identified as the most specific and common prodromal stages of α-synucleinopathies (αSYN) such as Parkinson's…
  • 2023 International Congress

    Development of an Item Bank for Assessing Psychosis in Parkinson’s Disease: A Systematic Review

    G. Mangone, M. Tosin, C. Goetz, G. Stebbins, T. Mestre (Chicago, USA)

    Objective: This study aimed to develop an item bank for assessing psychosis in Parkinson's disease (PD). Background: Psychosis is a common and debilitating symptom in…
  • 2023 International Congress

    Late onset cerebellar ataxia in patients treated with VIM DBS

    C. Héraud, C. Alecu, D. Fontaine, A. Leplus, C. Giordana (NICE, France)

    Objective: To highlight the predictors for onset of cerebellar ataxia in patients treated with deep brain stimulation (DBS) of the Thalamic Ventral Intermediate Nucleus (VIM)…
  • 2023 International Congress

    Impaired structural connectivity in Parkinson’s disease with probable RBD

    J. Oltra, I. Roura, A. Campabadal, C. Uribe, J. Pardo, MJ. Martí, Y. Compta, F. Valldeoriola, N. Bargallo, A. Iranzo, C. Junque, B. Segura (Barcelona, Spain)

    Objective: To characterize structural connectivity through whole-brain network-based statistics and graph theory implementation in treated Parkinson’s disease (PD) patients with probable REM sleep behavior disorder…
  • 2023 International Congress

    A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson’s Disease (PADOVA): Rationale, Design, and Baseline Data

    T. Nikolcheva, G. Pagano, N. Pross, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, K. Seppi, A. Monnet, N. Shariati, L. Rutten-Jacobs, S. Zanigni, T. Kustermann, K. Taylor, D. Trundell, H. Svoboda, A. Bonni, P. Fontoura, R. Doody (BASEL, Switzerland)

    Objective: The study will evaluate the efficacy and safety of prasinezumab in individuals with early-stage Parkinson's disease (PD) on stable symptomatic therapy. Background: Available treatments…
  • « Previous Page
  • 1
  • …
  • 426
  • 427
  • 428
  • 429
  • 430
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley